Back to top

Image: Bigstock

Immune Design Corp.

Read MoreHide Full Article

Immune Design’s third-quarter 2015 results were encouraging with the company posting a narrower-than-expected loss. The company’s efforts on developing its pipeline are also encouraging. Moreover, we are positive on its strategic agreements with companies like Sanofi, Roche, Merck and AstraZeneca, which not only validate its GLAAS platform, but also provides the company with funds in the form of collaboration and license revenues. Additionally, such collaborations boost the company’s pipeline development. On the flip side, dependence on other companies for revenue growth increases its vulnerability. Meanwhile, Immune Design’s pipeline candidates are in the early stages of development and thus, several years away from commercialization.

Published in